ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

Ceigall India shares rise 2.9% on new road, bulk drug park contracts

The engineering and construction firm secured contracts worth ₹7.05 billion and ₹225 crore for projects in Arunachal Pradesh and Himachal Pradesh, respectively. Shares advanced to ₹323.35.

PA
Priya Anand · Equities & Earnings Desk · 25 Aug 2026 · 22:21 · 1 min read
Share
Ceigall India shares rise 2.9% on new road, bulk drug park contracts

Shares of Ceigall India advanced 2.9% on Tuesday, closing at ₹323.35, after the engineering and construction company secured two major contracts from Indian government agencies.

The company won a ₹7.05 billion contract from India’s Ministry of Road Transport and Highways for road construction in Arunachal Pradesh. Separately, Ceigall obtained a Letter of Award from the Himachal Pradesh State Industrial Development Corporation for the development of a Bulk Drug Park in Una. The Una project, valued at ₹225 crore, is structured as a unit price contract with an 18-month execution timeline.

The Bulk Drug Park contract covers Phase I scope including land clearing, internal roads, stormwater drainage, a bridge, and fencing. These awards follow Ceigall’s strategy to diversify beyond its core highway and expressway operations, expanding into metro projects, solar energy, and industrial park development across multiple Indian states.

The stock’s 52-week range stands at ₹222.61 to ₹405.70. While broader Indian equity benchmarks have traded in a narrow range recently, Ceigall’s gains reflect domestic policy-driven order flow rather than external market cues, which have exerted mild pressure on U.S. indices.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT